SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: GARY P GROBBEL who wrote (100156)10/22/2010 3:24:04 PM
From: Ted M  Read Replies (1) of 120405
 
Wow, IVOB .06, as hoped to report results on Tuesday:

DENVER and BEVERLY, Mass., Oct. 22 /PRNewswire/ -- INVO Bioscience, Inc. (OTC Bulltin Board: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced that Dr. Elkin Lucena of the Columbian Fertility and Sterility Center (CECOFLES LTDA) will present the results of the first 95 fertility treatment cycles undertaken at the Center utilizing INVO Bioscience's INVOcell technology at the 66th Annual Meeting of the American Society for Reproductive Medicine on October 26, 2010 in Denver, Colorado.

The Annual Meeting of the American Society for Reproductive Medicine (ASRM) is one of the premier educational and professional networking conferences in the reproductive field. The theme for this year's event is "Taking Reproductive Medicine to New Heights." The event will feature a wide variety of postgraduate courses, lectures, symposia, roundtables, debates, abstracts, posters and videos focusing attention on the latest scientific developments in the field of reproductive medicine and their translation to clinical medicine.

Dr. Claude Ranoux, president of INVO Bioscience, commented, "We look forward with great anticipation to the CECOFLES presentation regarding the use of INVOcell in its initial treatment cycles. We are confident that INVOcell has performed well in these initial applications. Additionally, we are pleased that the study results have been accepted and will be unveiled at a prestigious conference the caliber of the ASRM."

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

Private Securities Litigation Reform Act of 1995
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext